| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
D-Praziquanamine is the inactive isomer of L-Praziquanamine and does not exhibit significant biological activity. It serves as an experimental control for studies involving the active L-enantiomer. (R)-Praziquantel, the active enantiomer of praziquantel, exhibits antiparasitic activity against juvenile S. mansoni infestations in mice. D-Praziquanamine is used as a reference compound in pharmacological research.
|
|---|---|
| ln Vitro |
D-Praziquanamine is the inactive isomer of L-Praziquanamine and does not exhibit significant biological activity in vitro. It is used as a control compound in experiments. (R)-Praziquantel, the active enantiomer, exhibits Schistosoma mansoni infestation inhibition in vitro. D-Praziquanamine itself shows no notable antiparasitic activity and is intended for use as an experimental control.
|
| ln Vivo |
In vivo studies of D-Praziquanamine are limited as the compound is an inactive isomer used primarily as an experimental control. (R)-Praziquantel, the active enantiomer, exhibits Schistosoma mansoni infestation inhibition in vivo. D-Praziquanamine itself does not exhibit significant in vivo activity and is not intended for therapeutic use. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for D-Praziquanamine typically involve testing its activity as a control compound for L-Praziquanamine studies. The compound's purity and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. It is used as an inactive control in binding assays to establish baseline activity and specificity of the active L-enantiomer.
|
| Cell Assay |
In vitro cell-based assays for D-Praziquanamine involve culturing cells to evaluate its effects as a control compound. Cells are treated with varying concentrations of the compound and compared to the active L-enantiomer. The compound is used to establish baseline activity and ensure that observed effects are specific to the active enantiomer. Cell viability is assessed using standard assays. All experiments are performed with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for D-Praziquanamine are limited as the compound is an inactive isomer used as a control. (R)-Praziquantel, the active enantiomer, has been studied in mouse models of Schistosoma mansoni infestation. D-Praziquanamine itself is not intended for in vivo efficacy studies. For control purposes, animals would be administered the compound and compared to active treatment groups. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
D-Praziquanamine has a molecular weight of 176.22 and the molecular formula C10H12N2O. The compound appears as a solid powder. As an inactive isomer, it does not exhibit the pharmacokinetic properties of the active enantiomer. Complete pharmacokinetic profiling of D-Praziquanamine would require further systematic studies, but the compound is primarily used as a control reagent rather than for pharmacokinetic evaluation.
|
| Toxicity/Toxicokinetics |
The toxicity profile of D-Praziquanamine is not well documented as the compound is primarily used as an experimental control. As an inactive isomer, it is expected to have lower biological activity and potentially lower toxicity compared to the active enantiomer. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
D-Praziquanamine (CAS# 55375-92-3) is also known as (-)-Praziquanamine. It has the molecular formula C10H12N2O and a molecular weight of 176.22. The compound is the (R)-enantiomer of praziquanamine and the inactive isomer of L-Praziquanamine. D-Praziquanamine can be utilized as a control compound in experiments. L-Praziquanamine is a naturally occurring compound. The compound is intended for research use only.
|
| Molecular Formula |
C12H14N2O
|
|---|---|
| Molecular Weight |
202.25
|
| Exact Mass |
202.11
|
| CAS # |
55375-92-3
|
| Related CAS # |
L-Praziquanamine;99746-73-3
|
| PubChem CID |
24797048
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
399.7±42.0 °C at 760 mmHg
|
| Flash Point |
195.5±27.9 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.633
|
| LogP |
0.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
266
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CN2[C@@H](CNCC2=O)C3=CC=CC=C31
|
| InChi Key |
GTRDOUXISKJZGL-NSHDSACASA-N
|
| InChi Code |
InChI=1S/C12H14N2O/c15-12-8-13-7-11-10-4-2-1-3-9(10)5-6-14(11)12/h1-4,11,13H,5-8H2/t11-/m0/s1
|
| Chemical Name |
(11bR)-1,2,3,6,7,11b-hexahydropyrazino[2,1-a]isoquinolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9444 mL | 24.7219 mL | 49.4438 mL | |
| 5 mM | 0.9889 mL | 4.9444 mL | 9.8888 mL | |
| 10 mM | 0.4944 mL | 2.4722 mL | 4.9444 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
